Naltrexone implants compared to methadone: Outcomes six months after prison release

European Addiction Research

Volumn 16, Issue 3, 2010, Pages 139-145

  Lobmaier, Philipp P ^a,b,d   Kunøe, Nikolaj ^a   Gossop, Michael ^a,c   Katevoll, Tormod ^b   Waal, Helge ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Norwegian Centre for Addiction Research   (Norway)

Author keywords

Heroin; Methadone; Naltrexone implants; Prison release; Relapse

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; ILLICIT DRUG; METHADONE; NALTREXONE; DRUG IMPLANT;

ABSTINENCE; ADULT; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRIMINAL BEHAVIOR; DECREASED APPETITE; DIARRHEA; DRUG DEPENDENCE; DRUG IMPLANT; DRUG IMPLANTATION; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEROIN DEPENDENCE; HUMAN; IRRITABILITY; MALE; METHADONE TREATMENT; MORTALITY; MYALGIA; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRISON; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; SUSTAINED RELEASE PREPARATION; CRIME; OPIOID-RELATED DISORDERS; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA;

ADULT; CRIME; DRUG IMPLANTS; FEMALE; HUMANS; MALE; METHADONE; NALTREXONE; OPIOID-RELATED DISORDERS; PRISONS; RECURRENCE; SECONDARY PREVENTION;

EID: 77951230451     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313336     Document Type: Article

References (62)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Statistical bulletin 2009. http://www.emcdda.europa.eu/ stats09/dup.
2. Mumola CJ, Karberg JC: Drug Use and Dependence, State and Federal Prisoners. Washington, U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics, 2006.
3. Cropsey KL, Villalobos GC, St Clair CL: Pharmacotherapy treatment in substancedependent correctional populations: a review. Subst Use Misuse 2005; 40: 1983-1988.
4. Pearson FS, Lipton DS: A meta-analytic review of the effectiveness of correctionsbased treatments for drug abuse. Prison J 1999; 79: 384-410.
5. Perry A, Coulton S, Glanville J, Godfrey C, Lunn J, McDougall C, Neale Z: Interventions for drug-using offenders in the courts, secure establishments and the community. Cochrane Database Syst Rev 2006; 3: CD005193.
6. Kreek MJ, Vocci FJ: History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23: 93-105.
7. Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-329.
8. Clausen T, Anchersen K, Waal H: Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94: 151-157.
9. Gossop M, Trakada K, Stewart D, Witton J: Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drug Alcohol Depend 2005; 79: 295-302.
10. Teesson M, Ross J, Darke S, Lynskey M, Ali R, Ritter A, Cooke R: One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 2006; 83: 174-180. (Pubitemid 43795472)
11. Stallwitz A, Stover H: The impact of substitution treatment in prisons - a literature review. Int J Drug Policy 2007; 18: 464-474.
12. Gonzalez JP, Brogden RN: Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192-213.
13. O'Brien CP, Greenstein RA, Mintz J, Woody GE: Clinical experience with naltrexone. Am J Drug Alcohol Abuse 1975; 2: 365-377.
14. Brahen LS, Henderson RK, Capone T, Kordal N: Naltrexone treatment in a jail work-release program. J Clin Psychiatry 1984; 45: 49-52.
15. Chan KY: The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: the first cohort. J Clin Forensic Med 1996; 3: 87-92.
16. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP: Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997; 14: 529-534.
17. Fram DH, Marmo J, Holden R: Naltrexone treatment - the problem of patient acceptance. J Subst Abuse Treat 1989; 6: 119-122.
18. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; 1:CD001333.
19. Comer SD, Sullivan MA, Hulse GK: Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007; 16: 1285-1294.
20. Lobmaier P, Kornør H, Kunøe N, Bjørndal A: Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 2:CD006140.
21. Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV: Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007; 91: 289-292.
22. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-218.
23. Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H: Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009; 194: 541-546.
24. Tait RJ, Ngo HT, Hulse GK: Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008; 35: 116-124.
25. Caplan AL: Ethical issues surrounding forced, mandated, or coerced treatment. J Subst Abuse Treat 2006; 31: 117-120.
26. Marlowe DB: Depot naltrexone in lieu of incarceration: a behavioral analysis of coerced treatment for addicted offenders. J Subst Abuse Treat 2006; 31: 131-139.
27. O'Brien C, Cornish JW: Naltrexone for probationers and parolees. J Subst Abuse Treat 2006; 31: 107-111.
28. Patapis NS, Nordstrom BR: Research on naltrexone in the criminal justice system. J Subst Abuse Treat 2006; 31: 113-115.
29. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, Koepsell TD: Release from prison - a high risk of death for former inmates. N Engl J Med 2007; 356: 157-165.
30. Bird SM, Hutchinson SJ: Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-1999. Addiction 2003; 98: 185-190.
31. La Vigne N, Visher C, Castro J: Chicago Prisoners' Experiences Returning Home. Washington, The Urban Institute, 2004.
32. Butzin CA, Martin SS, Inciardi JA: Treatment during transition from prison to community and subsequent illicit drug use. J Subst Abuse Treat 2005; 28: 351-358.
33. Hiller ML, Knight K, Simpson DD: Prisonbased substance abuse treatment, residential aftercare and recidivism. Addiction 1999; 94: 833-842.
34. Pelissier B, Jones N, Cadigan T: Drug treatment aftercare in the criminal justice system: a systematic review. J Subst Abuse Treat 2007; 32: 311-320.
35. Sheehan DV: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33.
36. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P: Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004; 9: 59-65.
37. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK: Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 23-28.
38. Waal H, Frogopsahl G, Olsen L, Christophersen AS, Morland J: Naltrexone implants - duration, tolerability and clinical usefulness. A pilot study. Eur Addict Res 2006; 12: 138-144.
39. World Health Organization (WHO): Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. 2009. Available online: http:// w h q l i b d o c . w h o . i n t / p u b l i c a - tions/2009/9789241547543-eng.pdf.
40. Waal H: Merits and problems in highthreshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Eur Addict Res 2007; 13: 66-73.
41. Kokkevi A, Hartgers C: EuropASI: European adaption of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995; 1: 208-210.
42. Sobell LC, Sobell MB: Timeline follow-back: a technique for assessing self-reported alcohol consumption; in Allen JP, Litten RZ, (eds): Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, Human Press, 1992, pp 41-72.
43. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
44. Office for Human Research Protections (OHRP): Guidance on the Involvement of Prisoners in Research. Department of Health and Human Services, 2003. http://www.hhs. gov/ohrp/humansubjects/guidance/prisoner. htm.
45. Lobmaier PP, Kunøe N, Waal H: Treatment research in prison: problems and solutions in a randomized trial. Addict Res Theory 2010; 18: 1-13.
46. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD: Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005; 100: 820-828.
47. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE: A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction 2008; 103: 1333-1342.
48. Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT, Wilson M: A randomized clinical trial of methadone maintenance for prisoners: results at 1-month postrelease. Drug Alcohol Depend 2007; 91: 220-227.
49. Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE: A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav 2008; 35: 34-47.
50. Shearer J, Wodak AD, Dolan KA: Evaluation of a prison-based naltrexone program. Int J Prison Health 2007; 3: 214-224.
51. Chiang CN, Hollister LE, Gillespie HK, Foltz RL: Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend 1985; 16: 1-8.
52. Willette RE: The development of sustained action preparations of narcotic antagonists. NIDA Res Monogr 1978; 19: 333-339.
53. Keegan J, Lavenduski C, Schooff K: Comments and findings from a naltrexone double blind study. NIDA Res Monogr 1976; 9: 74-76.
54. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-263.
55. Ehrman RN, Robbins SJ: Reliability and validity of 6-month timeline reports of cocaine and heroin use in a methadone population. J Consult Clin Psychol 1994; 62: 843-850.
56. Harrell AV: Validation of self-report: the research record. NIDA Res Monogr 1985; 57: 12-21.
57. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP: Lack of information in naltrexone study - reply. Arch Gen Psychiatry 2007; 64: 865-886.
58. Farrell M, Marsden J: Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 2008; 103: 251-255.
59. Seaman SR, Brettle RP, Gore SM: Mortality from overdose among injecting drug users recently released from prison: database linkage study. Br Med J 1998; 316: 426-428.
60. Stewart LM, Henderson CJ, Hobbs MS, Ridout SC, Knuiman MW: Risk of death in prisoners after release from jail. Aust NZ J Public Health 2004; 28: 32-36.
61. Rich JD, McKenzie M, Shield DC, Wolf FA, Key RG, Poshkus M, Clarke J: Linkage with methadone treatment upon release from incarceration: a promising opportunity. J Addict Dis 2005; 24: 49-59.
62. Shewan D, Gemmell M, Davies JB: Prison as a modifier of drug using behaviour. Addict Res Theory 1994; 2: 203-215.